| Methods |
Randomised, placebo‐controlled, double‐blind trial |
| Participants |
45 adults with SMA type III |
| Interventions |
Salbutamol or identical placebo tablets at the same dosing schedule |
| Outcomes |
Change in manual muscle testing, North Star Ambulatory Assessment scale, 6MWT and FVC.
Molecular analyses included SMN2 gene copy number, SMN2 transcript and SMN protein levels. |
| Notes |
Study completed, but results are awaiting. Unknown date of completion; last update received March 2012 on WHO International Clinical trials Registry Platform. |
